Newbridge Financial Services Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Newbridge Financial Services Group’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,000	Closed	-$137K	–	1492
2022 Q4	$137K	Hold	13,000	–	–	0.08%	242
2022 Q3	$59K	Hold	13,000	–	–	0.03%	415
2022 Q2	$52K	Hold	13,000	–	–	0.03%	401
2022 Q1	$95K	Hold	13,000	–	–	0.05%	317
2021 Q4	$73K	Hold	13,000	–	–	0.03%	371
2021 Q3	$83K	Hold	13,000	–	–	0.05%	296
2021 Q2	$110K	Buy	13,000 +6,500	+100%	+$52.4K	0.07%	266
2021 Q1	$68K	Hold	6,500	–	–	0.05%	328
2020 Q4	$110K	Hold	6,500	–	–	0.09%	212
2020 Q3	$83K	Buy	+6,500	New	+$82.1K	0.08%	220

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Newbridge Financial Services Group's PRVB Position: Q1 2023 in Review

Newbridge Financial Services Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 13,000 shares — an estimated $137K sold.

Newbridge Financial Services Group first reported a position in PRVB in Q3 2020 and held it in 10 quarters. The position peaked at $137K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

Newbridge Financial Services Group reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 13,000 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $137K.
Newbridge Financial Services Group first reported a position in Provention Bio, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
Newbridge Financial Services Group's Provention Bio, Inc. Common Stock position peaked at $137K in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on Newbridge Financial Services Group's 13F filing for Q1 2023, filed 18 Apr 2023.